Summary
69 / 100 · Bulios Score
What speaks for it
- Out of every 100 CNY of revenue, 21 CNY is left as net profit.
- It holds more cash than debt: ¥8.91B against ¥2.27B.
- Revenue grew by 13% a year over the last 3 years.
- Analysts expect revenue to grow by 20% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 31.6 CNY for 1 CNY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (CNY)
Diluted EPS (CNY)
- Analyst estimate
Revenue grew by 31% a year over 5 years. Over the last 3 years it grew by 13% a year. For the next fiscal year analysts expect revenue to grow by 20%. Earnings per share grew by 4.7% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 CNY of revenue goes
- Cost of sales 53 CNY
- Research and development 2.2 CNY
- Sales and administration 13 CNY
- Taxes and other 11 CNY
- Net profit 21 CNY
Net profit, industry median (Biotechnology) -7.1 CNY
Out of every 100 CNY of revenue, 21 CNY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail